ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 03:49:16 2024-04-16 pm EDT			5-day change	1st Jan Change
14.44 ^USD	+12.02%		+15.56%	-4.23%

Apr. 10	ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept	MT
Apr. 09	ALX Oncology Holdings Inc. Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (?R/R B-NHL?)	CI

ALX Oncology Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2021

February 28, 2022 at 07:57 am EST

ALX Oncology Holdings Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 83.46 million compared to USD 45.74 million a year ago. Basic loss per share from continuing operations was USD 2.07 compared to USD 2.76 a year ago.

Latest news about ALX Oncology Holdings Inc.

ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept	Apr. 10	MT
ALX Oncology Holdings Inc. Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (?R/R B-NHL?)	Apr. 09	CI
UBS Adjusts ALX Oncology Price Target to $25 From $27, Maintains Buy Rating	Mar. 13	MT
H.C. Wainwright Adjusts Price Target on ALX Oncology to $20 From $17.50, Keeps Buy Rating	Mar. 11	MT
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
Piper Sandler Adjusts Price Target on ALX Oncology Holdings to $21 From $11, Maintains Overweight Rating	Mar. 08	MT
Stifel Downgrades ALX Oncology Holdings to Hold From Buy, Adjusts Price Target to $14 From $10	Mar. 08	MT
ALX Oncology Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
ALX Oncology Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Transcript : ALX Oncology Holdings Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 through Jan-11-2024	Jan. 08
ALX Oncology Holdings Inc. and ALX Oncology Inc. Enter into the Third Amendment to Loan and Security Agreement	Dec. 26	CI
North American Morning Briefing : Investors Await -2-	Dec. 11	DJ
Top Midday Gainers	Dec. 08	MT
Jefferies Upgrades ALX Oncology to Buy From Hold, Adjusts Price Target to $18 From $8	Dec. 08	MT
Stifel Trims ALX Oncology Holdings' Price Target to $10 From $11, Maintains Buy Rating	Nov. 14	MT
Sector Update: Health Care Stocks Advance Premarket Tuesday	Nov. 14	MT
ALX Oncology Reports Q3 Results With 'Sufficient' Funds to Finance Operations Into Early 2026	Nov. 13	MT
ALX Oncology Q3 Net Loss Widens; Shares Ease After Hours	Nov. 13	MT
ALX Oncology Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Transcript : ALX Oncology Holdings Inc. Presents at UBS Biopharma Conference 2023, Nov-08-2023 01:30 PM	Nov. 08
Piper Sandler Raises Price Target on ALX Oncology to $11 From $8, Maintains Overweight Rating	23-10-11	MT
ALX Oncology Closes $63.2 Million Common Stock, Warrants Offering to Fund Clinical Development of Evorpacept	23-10-10	MT
ALX Oncology Prices Underwritten Offering of Common Stock, Warrants for Expected Gross Proceeds of $55 Million	23-10-05	MT
ALX Oncology Commences Common Stock, Warrants Offering to Fund Development of Evorpacept	23-10-04	MT
UBS Adjusts ALX Oncology Price Target to $27 From $29, Maintains Buy Rating	23-10-04	MT

Chart ALX Oncology Holdings Inc.

Duration

Period

More charts

Company Profile

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. Cancer cells leverage CD47, a cell surface protein, as a donât eat me signal to evade macrophage phagocytosis or as a don't activate T-cells signal that prevents activation of T-cells by dendritic cells. It focuses on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. It also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.89 USD

Average target price

20.17 USD

Spread / Average Target

+56.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALX ONCOLOGY HOLDINGS INC.	-4.23%	646M
VERTEX PHARMACEUTICALS INCORPORATED	-3.20%	103B
REGENERON PHARMACEUTICALS, INC.	+1.82%	96.56B
ARGENX SE	+1.72%	22.61B
BIONTECH SE	-17.78%	21.18B
GENMAB A/S	-4.50%	19.07B
WUXI APPTEC CO., LTD.	-41.75%	16.53B
BEIGENE, LTD.	-25.65%	14.46B
NEUROCRINE BIOSCIENCES, INC.	+1.53%	13.25B
SAREPTA THERAPEUTICS, INC.	+21.43%	11.1B

Bio Therapeutic Drugs